Source link : https://www.newshealth.biz/health-news/empagliflozin-may-slow-diabetic-retinopathy/
TOPLINE: Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not reduce the risk for incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase 4 (DPP-4) inhibitors in patients with type 2 diabetes, but the drug did reduce the risk for its progression by 22% in patients with existing retinopathy. METHODOLOGY: Researchers conducted a new-user active-comparator cohort […]
Author : News Health
Publish date : 2024-12-06 12:54:41
Copyright for syndicated content belongs to the linked Source.
inHealth